Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Long-Term Debt Repayments (2022 - 2025)

Harmony Biosciences Holdings' Long-Term Debt Repayments history spans 4 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments rose 33.33% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $16.2 million, up 8.33%, while the annual FY2025 figure was $16.2 million, 8.33% up from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $5.0 million at Harmony Biosciences Holdings, up from $3.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $5.0 million in Q4 2025 and bottomed at $500000.0 in Q1 2022.
  • The 4-year median for Long-Term Debt Repayments is $3.8 million (2023), against an average of $2.5 million.
  • The largest YoY upside for Long-Term Debt Repayments was 650.0% in 2023 against a maximum downside of 0.0% in 2023.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $500000.0 in 2022, then soared by 650.0% to $3.8 million in 2023, then changed by 0.0% to $3.8 million in 2024, then soared by 33.33% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Long-Term Debt Repayments are $5.0 million (Q4 2025), $3.8 million (Q3 2025), and $3.8 million (Q2 2025).